[Propanc Biopharma and Hexstone Capital Reach $100 Million Strategic Financing Agreement] On October 15, biopharmaceutical company Propanc Biopharma announced that it has reached a strategic financing agreement of up to $100 million with family office Hexstone Capital. The company is adopting an Ethereum treasury strategy, aiming to accelerate the development of its clinical pipeline through this financing and increase the value of its digital asset portfolio to $100 million or more within the next 12 months. Propanc CEO James Nathanielsz emphasized that this move will advance the company's presence in the digital asset sector. Hexstone Capital has previously invested in multiple enterprises holding digital assets such as $BTC, $ETH, $SOL, and $DOGE. Notably, Propanc had announced plans in early September to acquire $100 million worth of Ethereum assets.